The global market for micro servers is observing massive call for competent computing goods, which has obliged market players to upturn their concentration on product invention and development of the current assortment. Mergers, acquisit…
BMI View: An expected increase in US government funding to strengthen Puerto Rico's healthcare system
will support pharmaceutical and healthcare sector growth in the commonwealth over the next few years.
While the US administration will continue to seek legislative removal of Puerto Rico's Medicaid funding
limitations over the coming months, the increasing risk posed by the Zika virus outbreak in the territory will
push for a rise in healthcare funding to become a priority. That said, market growth rates in several
segments, including pharmaceuticals, are set to face headwinds due to Puerto Rico's economic recession.
Headline Expenditure Projections
? Pharmaceuticals: USD3.81bn in 2015 to USD3.82bn in 2016; +0.2%. Forecast in line with last quarter.
? Healthcare: USD8.06bn in 2015 to USD8.37bn in 2016; +3.8%. Forecast broadly in line with last
In Q416, we have revised upwards Puerto Rico's Risk/Reward Index score to 65.7 from 64.5 in the last
quarter (out of 100). The score revision was driven by an improvement in the Industry Rewards index.
Puerto Rico continues to stand as the third most attractive market to pharmaceutical investors in the
Americas region, behind the US and Canada. Puerto Rico's score is driven by high spending per capita on
medicine and high patent respect and business environment scores, but dragged down by a small market
size and low sector value growth.
? In August 2016, Inovio Pharmaceuticals initiated a trial of its preventative Zika vaccine, GLS-5700, in
Puerto Rico. Inovio, which is developing GLS-5700 in collaboration with GeneOne Life Science and
academic collaborators from the US and Canada, commenced the first FDA-approved human trial of a
Zika vaccine in June 2016.